230 results about "Serum protein" patented technology

The invention discloses a viral ARDS prognosis evaluation system based on protein joint detection, and the system comprises a sample processing module which is used for carrying out serum standardization pretreatment; the protein detection module is used for performing iBAQ quantification of IL6ST / FOXO3 / TLR7 based on DIA mass spectrometry, defining a targeted therapy threshold value and realizing targeted quantification of the core protein; and the intelligent analysis module is used for realizing cross-age risk layering based on a multivariable logic regression model. B cell function states are reflected by combining serum IL6ST / FOXO3 / TLR7 protein expression levels, a multivariable logistic regression model is constructed, and unified risk stratification of patients of all ages from children to the elderly is achieved; by locking an IL6ST / FOXO3 / TLR7 pathway, a targeted therapy threshold is defined to directly guide targeted therapy, and immune intervention is facilitated.

The invention relates to the technical field of ultrasonic and molybdenum target detection, in particular to an intelligent breast lump diagnosis system based on ultrasonic-molybdenum target multi-modal image and serum P16 protein detection, and the intelligent breast lump diagnosis system is characterized in that an ultrasonic image, a molybdenum target image and multi-modal data of serum P16 protein detection are fused; and optimal integration of cross-modal features is realized through a dynamic weight strategy. The ultrasonic image provides morphological and hemodynamic information of the lumps; the molybdenum target image reveals the characteristics of calcification density, calcification cluster heterogeneity, structure distortion depth and the like; serum P16 protein detection prompts malignant risks from the molecular level, and especially has important value in early recognition of triple negative breast cancer. A feature association graph is constructed through a graph neural network (GNN), the weight is dynamically adjusted in combination with a Bayesian probability integration formula, and optimal fusion of different modal features is ensured. The limitation of a single mode is made up, and the sensitivity and the specificity of diagnosis are also remarkably improved.

The invention discloses a synergistic dual-mode anticoagulation and anti-inflammatory central venous catheter BC-BCD double-layer bionic hydrogel coating and a preparation method thereof. BSA / CBAA hydrogel formed by copolymerizing bovine serum albumin and carboxyl betaine acrylamide is used as an outer coating of the catheter, dopamine containing catechol groups is introduced as a main chain network, and BSA / CBAA / DA hydrogel is obtained and used as an inner coating of the catheter. The two layers are combined through a two-step impregnation method to obtain the BC-BCD double-layer bionic coating, thrombus can be defended on a catheter interface in an active mode and a passive mode, oxidation factors in a body can be removed, oxidative stress and bacterial infection can be reduced, and the BC-BCD double-layer bionic coating can be tightly attached to a base material. Experimental results show that the prepared bionic hydrogel coating has excellent anticoagulation and anti-inflammatory performance and long-term stable adhesion performance, the main defects of a traditional central venous catheter are remarkably overcome, and the bionic hydrogel coating has a positive effect on clinical prevention of thrombus and infection.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The invention discloses a brain nerve cell targeted gene protein co-loaded nano delivery system and a preparation method thereof, phenylboronic acid modified polyethyleneimine is synthesized through substitution reaction, then the polyethyleneimine is compounded with DNA through electrostatic interaction to form a PEI-PBA / DNA nano compound, bovine serum albumin is loaded through nitrogen-boron complexation, and the brain nerve cell targeted gene protein co-loaded nano delivery system is obtained. The preparation method comprises the following steps: preparing a gene-protein co-loaded nano delivery system PPDB, further endowing the nano delivery system with a function of crossing a blood brain barrier, and introducing glycerophosphorylcholine through the formation of a borate bond, so as to prepare the cerebral nerve cell targeted gene-protein co-loaded nano system PPDBG. The preparation method disclosed by the invention is simple, realizes simultaneous loading of genes and proteins with completely different physical structures, and has very important research significance on brain-related diseases such as epilepsy and the like. Meanwhile, the introduction of the boric acid ester bond endows the nano delivery system with the on-demand plug-and-play characteristic, so that the spectral applicability of the nano delivery system is realized.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention relates to the technical field of reagent preservation, in particular to biotinylated tyrosine phosphatase antigen preservation liquid as well as a preparation method and application thereof. The pH value of the biotinylated tyrosine phosphatase antigen preserving fluid is 7.0-7.5, and the biotinylated tyrosine phosphatase antigen preserving fluid is prepared from the following raw material components: a buffering agent, soluble metal salt, an organic dispersing agent, poly (ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) 8400, a metal ion complexing agent, bovine serum albumin, a protein protective agent and a preservative. By optimizing the components of the biotinylated tyrosine phosphatase antigen preserving fluid, when the prepared antigen preserving fluid is used for preserving a biotin-labeled tyrosine phosphatase antigen, the storage life is greatly prolonged under the condition of 2-8 DEG C. The biotinylated tyrosine phosphatase antigen preserving fluid prepared by the method is convenient to use, stable to store, economical and practical, and simple to prepare.

The utility model relates to a bovine serum albumin purification device, and aims to improve the dropping precision of a salt solution in a protein purification process through automatic design and accurate control. The device comprises a pump box, a conveying wheel set, a liquid conveying rubber pipe, a driving motor and a liquid storage tank. The driving motor drives the conveying wheel set to rotate, and the abutting roller in the conveying wheel set revolves around the main shaft sleeve to extrude the liquid feeding rubber pipe, so that the salt solution is pushed to move along the pipeline, and accurate dripping of the liquid is realized. A groove gland is arranged on one side of the pump box and used for pressing the liquid conveying rubber pipe when the conveying wheel set is not started, and liquid leakage is prevented. The arrangement of the adjusting disc allows the abutting roller to be adjusted in the radial direction so as to adapt to liquid feeding rubber pipes of different specifications, and therefore the output amount of the salt solution is accurately controlled. The device is simple in structure and convenient to operate, can effectively improve the purification efficiency and quality of bovine serum albumin, and is suitable for various experiments and production environments.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The application belongs to the technical field of biomedical engineering, and specifically discloses a nano gene composition for treating brain glioma and a preparation method thereof, which is synthesized from bovine serum albumin loaded manganese dioxide particles, PLGA, DSPE-PEG3000 and DSPE-PEG-Angiopep2 as raw materials; the average particle size of the nano gene composition is 122.18±31.3 nm. The application also discloses a preparation method of the nano gene composition. The nano gene composition provided by the application encapsulates miRNA-138 in PLGA to avoid the degradation of miRNA-138 by RNA enzymes in the body, and simultaneously utilizes the targeting property of Angiopep2 to target the delivery of the nano gene composition to tumor tissues, to deliver microRNA into the brain while reducing tumor hypoxia and increasing the sensitivity of cells to X-ray irradiation, so as to realize multidirectional comprehensive treatment of glioblastoma.

The invention relates to the technical field of biological medicines, and provides a polypeptide targeting a BRAF dimer and an application of the polypeptide in tumor resistance, the polypeptide takes a straight-chain peptide TRHVNILLFM-OH as a peptide chain template, the straight-chain peptide is constructed through specific amino acid replacement, the C terminal is gradually truncated and cyclized to construct a cyclic peptide, and a specific sequence is coupled to develop a composite peptide strategy for modification, so that the polypeptide targeting the BRAF dimer is obtained. The cyclic peptide CBF-2, the cyclic peptide CBF-2-2 and the cyclic peptide SCBF-2-2 are obtained. Experiments prove that the polypeptide can effectively inhibit proliferation and invasion of tumor cells; the serum protein has high stability and excellent cell penetrating capability, and can penetrate through a cell membrane to enter cytoplasm, so that target protein in cells can be better targeted to exert biological functions of the target protein. Therefore, the multi-functional composite peptide can be developed through a polypeptide modification strategy, the membrane permeability and the stability of the multi-functional composite peptide are improved, the binding force of the multi-functional composite peptide and the BRAF protein is further improved, and the effects of inhibiting proliferation of tumor cells and resisting invasion are achieved at the same time.

The application discloses a preparation method and application of a polyacid tannic acid modified ultrafiltration membrane, and the preparation method comprises the following steps: preparing a casting solution containing a high molecular film forming material and a solvent; adding a polyoxometalate into the casting solution, uniformly mixing, and obtaining a polyacid modified casting solution; scraping and coating the polyacid modified casting solution to form a liquid membrane, pre-evaporating, immersing into a coagulation bath containing tannic acid to perform phase inversion and film forming, and obtaining the polyacid tannic acid modified ultrafiltration membrane. Through the synergistic effect of the polyacid blending regulation of the membrane pore structure and the in-situ coordination modification of the tannic acid phase separation, the simultaneous improvement of the permeation flux and the retention rate is realized, the pure water flux of the obtained ultrafiltration membrane reaches 221.37 LMH, the bovine serum albumin retention rate reaches 96.17%, and the preparation process is simple, efficient, and has a good large-scale application prospect.

The present invention provides a cryopreservation solution for Koi herpesvirus, as well as its preparation method and application, relating to the field of virus preservation technology. The solution comprises 2-8 w / v% hydroxyethyl starch, 3-5 w / v% sucrose, and 1-3 w / v% bovine serum albumin. The Koi herpesvirus has an activity of ≥90% after resuscitation, can withstand five freeze-thaw cycles, can be stably frozen at -20°C, and has a shelf life of up to two years. This solution solves the technical problems in the prior art, such as the need to store cryopreservation solutions at ultra-low temperatures, the risk of osmotic pressure imbalance and viral envelope rupture, and low activity after cryopreservation and resuscitation.

The application discloses a micro serum tumor whole-process screening detection method based on nucleic acid aptamer group comparison, and comprises the following steps: firstly, 24+1 tumor and non-tumor specific nucleic acid aptamer groups are screened by using bidirectional thermal cycle subtraction SELEX technology; data of the specific nucleic acid aptamer groups are used to create a standard database; the specific nucleic acid aptamer groups are mixed in equal proportions to develop 24+1 tumor and non-tumor specific nucleic acid aptamer detection reagents; in the detection process, the detected sample forms a magnetic bead-sample serum protein complex, and then is combined with the aptamer detection reagent; a magnetic bead-serum protein-sample specific nucleic acid aptamer complex is formed, and sample specific nucleic acid aptamer is separated and obtained; and the sample specific nucleic acid aptamer is compared and analyzed with the standard database, so that the sample detection technology method is realized. The method has the advantages of small sample amount, automatic process completion, high throughput, wide tumor screening range and the like, and meets the requirements of high-throughput tumor screening.

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

The application belongs to the field of biotechnology, and particularly relates to application of UBQLN1 protein in a cirrhosis diagnosis product, a kit and an in vitro detection method. The application comprises: using serum UBQLN1 protein as a marker, and applying the marker in preparation of a product for diagnosing or assisting in diagnosing cirrhosis; or applying the marker in preparation of a product for distinguishing cirrhosis from healthy individuals; or applying the marker in preparation of a product for evaluating progression of cirrhosis or a degree of liver fibrosis; and applying the marker in screening or evaluating a drug for preventing and / or treating cirrhosis.

The invention discloses a supramolecular fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of nano material application. The supramolecular fluorescent probe is formed by compounding gold nanoclusters and a bovine serum albumin solution, and the concentration ratio of the gold nanoclusters to the bovine serum albumin solution is (1-2): (2-4). The invention further discloses a preparation method of the supramolecular fluorescent probe and application of the supramolecular fluorescent probe. A fluorescent sensing system of the supramolecular fluorescent probe based on the gold nanocluster material and the bovine serum albumin has excellent selectivity and sensitivity on cypermethrin pesticide, interference of other impurities can be effectively avoided, and response is fast.

The application discloses a kind of ratio fluorescent sensor based on smart phone and its preparation method and application, the preparation method includes: after mixing chloroauric acid, bovine serum albumin, sodium hydroxide, gold cluster reaction liquid is obtained;Sodium citrate, 3-aminopropyl triethoxysilane, glycerol are mixed to obtain silicon quantum dot solution;Silicon quantum dot solution, lipopolysaccharide aptamer, EDC, NHS are reacted in ultrapure water to obtain aptamer modified silicon quantum dots;Lipopolysaccharide aptamer modified silicon quantum dots and gold cluster are mixed to obtain ratio fluorescent sensor.The ratio fluorescent sensor based on smart phone prepared by the application has good stability, strong specificity, can exclude fluorescent interference in environmental matrix, and is used for lipopolysaccharide analysis and detection by combining the colorimetric analysis of color picker of smart phone, so that in-vitro naked-eye visible rapid quantitative detection of lipopolysaccharide can be realized, to meet the demand of on-site monitoring.

The invention relates to the technical field of biomedicine, in particular to a serum protein marker for ossification of ligamentum flavum and application of the serum protein marker. The serum protein marker comprises erythrocyte glucose phosphate isomerase and / or dystrophin associated glycoprotein 1. According to the method, a data-independent quantitative proteomics strategy is utilized to compare a normal healthy control (a patient who does not suffer from ligamentum flavum ossification and needs spinal surgery to take ligamentum flavum tissues) with a ligamentum flavum ossification patient; it is found that ligamentum flavum ossification-related proteins, namely erythrocyte glucose phosphate isomerase (GPI) and dystrophy protein-related glycoprotein 1 (DAG1), with the obviously-changed expression quantity in tissue are beneficial to diagnosis of patients with ligamentum flavum ossification and provide effective targets for development of treatment methods of the ligamentum flavum ossification.

The invention discloses a dipeptide modified polymer and application thereof in intracellular delivery of protein. The screened polymer and protein form a compound and are subjected to phase transformation, solute in a liquid phase is transformed into solid-phase particles insoluble in water, early release of the target protein is reduced, and delivery of the protein in the presence of serum is achieved. The protein intracellular delivery method provided by the invention has relatively high intracellular delivery efficiency in the presence of serum-free protein and serum, and the delivery efficiency is higher than that of a commercial protein transfection reagent PULSin; after beta-Gal and other enzyme proteins are delivered into cells, the activity can be recovered, a catalytic substrate is converted into a monitorable product, and the amount of the delivered and active recovered protein is less affected by serum protein in incubation conditions; in addition, the material has low cytotoxicity, the cell activity is higher than 90% under the experimental condition of protein delivery, and the material has good biocompatibility.

The invention provides a liquid laccase protective agent and application thereof, and belongs to the technical field of bioengineering. According to the liquid laccase protective agent, a NaOH buffer solution with the pH value of 10.0 is used as a solvent, and solutes comprise trehalose, bovine serum albumin, glycine, Tween 80, sodium alginate, glycerin and copper chloride; the liquid laccase protective agent can effectively reduce the enzyme activity loss of laccase in the storage and transportation processes, prolong the storage life of the laccase and improve the application effect of the laccase, so that the application cost of the laccase is reduced, the application of the liquid laccase in the fields of food processing, papermaking industry, textile industry, industrial wastewater treatment and the like is facilitated, and the liquid laccase protective agent has good practicability.

The invention provides a biomarker for diagnosing primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises serum protein and / or N-glycopeptide. According to the method, the improvement of PBC diagnosis is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive prediction means for differential diagnosis of PBC is provided, and a theoretical basis is provided for rapid and accurate diagnosis of PBC.

The utility model relates to the technical field of cosmetic packaging, in particular to a serum protein active water film vacuum fresh-keeping glass bottle packaging device. The device comprises a storage assembly and a pumping assembly, the pumping assembly is connected with the storage assembly and extracts objects stored in the storage assembly outwards, the pumping assembly is externally connected with a smearing assembly, sealing assemblies are installed on the storage assembly and the smearing assembly, and the sealing assemblies control opening and closing installation. The storage assembly is designed to be in vacuum sealing, contact between oxygen in air and a serum protein active water film is remarkably reduced, the oxidation risk is reduced, the shelf life of the product is prolonged, the pumping assembly can accurately control the dosage extracted each time, waste is avoided, meanwhile, it is ensured that the dosage used each time is consistent, and the service life of the product is prolonged. The pumping mechanism reduces the opportunity that fingers of a user make direct contact with the product, pollution risks are reduced, product sanitation is guaranteed, the external smearing assembly is designed to be suitable for direct use, intermediate operation steps are reduced, and the user can smear the product easily.

The invention discloses a hybrid material for a cigarette filter stick and a preparation method and application thereof, the preparation method comprises the following steps: adding bovine serum albumin and 25wt% ammonia water into an ethanol water solution, and uniformly stirring to obtain a mixed solution; adding tetraethoxysilane into the mixed solution, continuously stirring for at least 30 minutes, adding dopamine hydrochloride at the concentration of 0.1 mol / L, and stirring at the temperature of 0-15 DEG C for at least 24 hours to obtain a pre-solution; carrying out hydrothermal reaction on the preposed solution at the temperature of 150 DEG C, and carrying out centrifugal filtration and washing to obtain a solid, namely the hierarchical pore structure hybrid nano material SiO2 (at) PDA. By the adoption of the composite filter stick, the reduction rate of the tar release amount can reach 37%, the tar release amount is reduced, meanwhile, the fragrance and physiological satisfaction of low-tar cigarettes can be remarkably improved, and the defect that the low-tar cigarettes are insufficient in sensory enjoyment is overcome.

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The present application relates to the technical field of separation and extraction, and particularly relates to a separation device for serum protein extraction, which comprises a reaction tank and a stirring rod, the stirring rod is provided with stirring blades rotating with the stirring rod, the reaction tank is fixedly provided with a stirring motor, and the separation device further comprises: a driving shaft vertically arranged in the reaction tank and deviated from the central position of the reaction tank, the stirring motor is used for driving the driving shaft to rotate; a mounting frame comprising a first connecting part and a second connecting part, the first connecting part is sleeved on the driving shaft and rotationally connected with the driving shaft, and the second connecting part is used for rotationally mounting the stirring rod; a transmission assembly is arranged between the driving shaft and the stirring rod, the stirring rod is driven to rotate by the driving shaft; and a driving assembly is used for driving the first connecting part to rotate, so that the stirring rod swings around the driving shaft. The stirring rod is stirred during swinging in the reaction tank, the uniformity of mixing is improved, and the problem of local over-acidification is reduced.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.